KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) EBITDA Margin: 2013-2025

Historic EBITDA Margin for Xenon Pharmaceuticals (XENE) over the last 9 years, with Mar 2025 value amounting to -856.95%.

  • Xenon Pharmaceuticals' EBITDA Margin was N/A to -856.95% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,531.58%, marking a year-over-year change of. This contributed to the annual value of -1,368.91% for FY2022, which is 94046.00% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its EBITDA Margin stood at -856.95% for Q1 2025, which was up 97.11% from -29,632.58% recorded in Q3 2022.
  • In the past 5 years, Xenon Pharmaceuticals' EBITDA Margin registered a high of -198.14% during Q1 2022, and its lowest value of -29,632.58% during Q3 2022.
  • Moreover, its 1-year median value for EBITDA Margin was -856.95% (2025), whereas its average is -856.95%.
  • Data for Xenon Pharmaceuticals' EBITDA Margin shows a peak YoY increase of 17,035bps (in 2022) and a maximum YoY decrease of 2,928,595bps (in 2022) over the last 5 years.
  • Over the past 3 years, Xenon Pharmaceuticals' EBITDA Margin (Quarterly) stood at -664.65% in 2021, then plummeted by 2,928,595bps to -29,632.58% in 2022, then reached -856.95% in 2025.
  • Its EBITDA Margin was -856.95% in Q1 2025, compared to -29,632.58% in Q3 2022 and -3,597.95% in Q2 2022.